Research on the link between expedited review and drug reevaluation from the perspective of innovation incentive based on American experienceZHANG Li-yang, YAN Jian-zhou, SUN Yuan-yuan, SHAO Rong2625-2630
Empirical analysis on technology innovation and firm growth of Chinese pharmaceutical enterprises with the supply side perspectiveLU Wei, WU Xiao-ming2631-2639
Analysis of international patents for cardiovascular drugsHAN Ling-ge, FENG Min, SONG Bo-wen, TANG Li2640-2645
Development of drug priority review system in China and relevant considerationGAO Lei, DI Yun-rui, HUANG Qing-zhu2656-2663
Protective effects of Qianggushengxue oral liquid on chemotherapy-induced bone marrow suppression in miceLUO Gui-fang, TANG Ya-hui, WU Li-feng, LIU Yue, XU Zhi, ZENG Gui-rong, XIN Hong-ya2664-2671
Research progress in the study of small-molecule PROTACs induced protein degradationXU Peng-fei, CHEN Yu, QIU Xia-qiu, GE Rao-ling, XIE Zhou-ling, BIAN Jin-lei, LI Zhi-yu2672-2680
Research progress in quantitative analysis methods of new immunosuppressants in human bloodYIN Hang, GENG Fang, LI Zhe, WANG Zheng, SHEN Su, YU Jun-xian, WANG Ru-long2681-2687
Progress in researches on evaluation models of placental transferXIA Yan-ming, DONG Ying, DI Liu-qing, ZHAO Xiao-li2688-2692